Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA
Key facts
- Who runs it
- Robert Ferris
- Where
- Pittsburgh, United StatesSee the 3 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- Sept 2016
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- Semi-allogenic human fibroblast (MRC-5) transfected with DNA
- Record updated
- 7 September 2017
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (36)Hide the full registry criteria
Who can take part
- Pathological stage I-IVa HNSCC
- The subject must have a complete removal of the primary HNSCC lesion with negative gross and microscopic margins. Documentation of margins by frozen sections at surgery is recommended. Patients who have already had surgery and have available banked tumor samples can be enrolled AFTER surgery
- At least 18 years of age
- Karnofsky performance status >/= 70
- Adequate hematologic function:
- Absolute neutrophil count > 1,000/mm3
- Absolute lymphocyte count > 1,000/mm3
- Hemoglobin > 9 g/dL
- Platelets > 100,000/mm3
- Liver function tests:
- Bilirubin (total) < /=1.7 mg/dL
- Alkaline phosphatase < 252 u/L
- SGOT < 108 u/L
- Kidney profile:
- Serum electrolytes
- Sodium 136-146 mEq/L
- Potassium 3.5-5.0 mEq/L
- Bicarbonate 21-31 mEq/L
- Chloride 98-107 mmol/L
- Serum creatinine < 3 x ULN
- BUN 8-26 mg/dL
- At least a 12 week interval should have elapsed between prior surgery, radiation therapy, chemotherapy or any other treatment and the first vaccination. Patients should have recovered from surgery and adjuvant treatment
- The effects of the tumor DNA-transfected fibroblast vaccine on the developing human fetus are unknown. For this reason women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 4 months after the last dose of the study vaccine, even if oral contraceptives are used. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of the tumor DNA-transfected fibroblast vaccine administration
Who cannot take part
- A significant history or current evidence of cardiac disease including, but not limited to: congestive heart failure, coronary artery disease, angina pectoris, uncontrolled hypertension, serious arrhythmias or myocardial infarction within the previous six months
- Active intracranial metastases. Patients with previously resected intracranial disease and/or previously irradiated intracranial metastases that have been clinically stable for four weeks are eligible
- Pregnant or lactating women. Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test per standard of care prior to the surgery for tumor removal. A second pregnancy test must be performed 7 days prior to the first vaccination and must be negative. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated on study
- Patients requiring systemic corticosteroids (unless patients have had no corticosteroids within 4 weeks prior to start of study)
- HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study. HIV testing will be performed in patients receiving combination anti-retroviral therapy when indicated per medical records review
- Evidence of ongoing or active infection requiring antibiotic therapy
- Autoimmune disease including, but not limited to, rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, or ankylosing spondylitis
- Patients who have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the patient to receive protocol treatment
- No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the patient has been disease-free for at least 5 years prior to registration
- Uncontrolled intercurrent illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements
- Patients with clinical symptoms of Hepatitis B and/or Hepatitis C will be tested, if clinically indicated per medical records review. Positive results will be an exclusion criteria
- Patients will be EXCLUDED from participation in the study if any of the following apply:
- One or more of the Inclusion Criteria are not met
Where in United States
- University of Pittsburgh Cancer Institute-Hillman Cancer CenterPittsburgh, United States
- University of Pittsburgh Medical Center - Shadyside HospitalPittsburgh, United States
- University of Pittsburgh Medical Center, Presbyterian HospitalPittsburgh, United States
About the trial
What the trial wants to find out
Hypothesis The incidence of toxicity in patients receiving the tumor DNA-transfected fibroblast vaccine will be acceptably low and the immunologic response rate sufficiently high to warrant further study of this therapy
Read full original descriptionShow less
The study of the vaccine will proceed in two stages after the method of Simon (102). In the first stage, 15 patients will be accrued and treated. If two or fewer objective immunologic responses occur, the study will be terminated. If 3 or more responses are observed, the study will proceed to the second stage, accruing an additional 22 patients. If the second stage is complete and a total of 9 or more immunologic responses are observed among the 37 patients treated, the treatment response rate for the vaccine will be considered high enough to warrant further study. Conversely, if the evaluation of the vaccine concludes at the first stage, or if 8 or fewer total immunologic responses occur after completing the second stage, the vaccine will not be considered for further study.
The group in the trial
- VaccineTreatment being tested
The vaccine is composed of lethally irradiated semi-allogenic human fibroblasts (MRC-5) transfected with genomic tumor DNA from the patients own tumor.
Treatment: Semi-allogenic human fibroblast (MRC-5) transfected with DNA
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Active Immunization of Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Using Fibroblasts Transfected With DNA From Autologous Tumor
- Record updated
- 7 September 2017